Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Nanchang UniversityActive in the last 2 years

Enliang Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2988-0323; OpenAlex author ID A5085416118. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 4

  1. Age and sex-dependent tumor microbiome programs shape pancreatic cancer prognosis. Last author DOI 10.1016/j.isci.2026.116542↗
  2. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Co-author DOI 10.2217/imt-2021-0075↗
  3. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Co-author DOI 10.1038/s41467-021-24769-3↗
  4. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. Co-author DOI 10.1186/s13046-021-02055-w↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 3 shared papers, 2021–2023 · strength 0.53
  2. Jian Xu · 2 shared papers, 2021–2023 · strength 0.34
  3. Xiaozhen Zhang · 2 shared papers, 2021–2023 · strength 0.34
  4. Gang Zhang · 2 shared papers, 2021 · strength 0.31
  5. Xing Huang · 2 shared papers, 2021 · strength 0.31
  6. Shuaiwu Luo · 1 shared paper, 2026 · strength 0.25
  7. Jun Yang · 1 shared paper, 2026 · strength 0.25
  8. Pengcheng Zhou · 1 shared paper, 2026 · strength 0.25
  9. Long‐Yun Ye · 1 shared paper, 2026 · strength 0.25
  10. Qi Chen · 1 shared paper, 2023 · strength 0.22
  11. Dipesh Kumar Yadav · 1 shared paper, 2021 · strength 0.12
  12. Mengyi Lao · 1 shared paper, 2021 · strength 0.12
  13. Tianyu Tang · 1 shared paper, 2021 · strength 0.12
  14. Xueli Bai · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.